Taysha Gene Therapies

Taysha Gene Therapies is a clinical-stage biotechnology company headquartered in Dallas, Texas. Employing 68 individuals, the company generates approximately $50 million in annual revenue. Taysha Gene Therapies specializes in developing adeno-associated virus (AAV)-based gene therapies for severe, single-gene disorders affecting the central nervous system. Their primary focus is on treating Rett syndrome, a rare neurodevelopmental disorder currently lacking effective disease-modifying therapies. The company distinguishes itself through its commitment to developing transformative medicines, aiming to address significant unmet medical needs and improve the lives of patients with severe neurological conditions. Taysha leverages its experienced management team, advanced manufacturing processes, and clinically proven AAV9 capsid technology to expedite the translation of treatments from research to clinical application. For more information, visit Taysha Gene Therapies' website at tayshagtx.com.